NASDAQ: SERA · Industrial Applications and Services · 3 alerts · CIK 1534969
Share price
$1.94Close, Nov 16
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Sera Prognostics, Inc. filings on SEC EDGAR ↗
Sera Prognostics, Inc. reported its financial results for the quarter ended September 30, 2026, highlighting continued commercialization efforts for its PreTRM test. The company maintained a strong cash position while focusing on expanding clinical evidence and market adoption to drive long-term growth.
Sera Prognostics reported Q3 2026 financial results, highlighting a 54% sequential increase in PreTRM test volume and a five-fold increase since Q1 2026. The company secured Medicaid coverage for its test in Florida, following a similar win in Illinois, and ended the quarter with $72.8 million in cash and marketable securities.
Term
Q3 2026
“The third quarter marked an important step forward as we continued our transition from evidence generation to commercial execution. We delivered strong growth in physician adoption and test volume, saw expanded reimbursement through a second state Medicaid coverage win in Florida, advanced our commercial payer initiatives, and continued to strengthen our clinical and health economic evidence base.”
Zhenya Lindgardt, President and Chief Executive Officer
Sera Prognostics CMO Tiffany Eul Davis Inglis Sells $16.3K of Stock
Tiffany Eul Davis Inglis, CMO, sold 8,024 shares of Sera Prognostics, Inc. at $2.03 a share, worth $16.3K in total on Oct 12, 2026. Shares held after the trade: 83,565 (-8.8%).